Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Plans To Restart Tanezumab Trials In 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.

Advertisement

Related Content

Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Lilly’s Glyxambi Is First SGLT2/DPP-4 Combo Product For Diabetes
Biopharma Dealmaking Quarterly Statistics, Q4 2013
As Eliquis Sales Lag, Bristol/Pfizer Take Action
Anti-NGF Trials Might Resume With Very Narrow Patient Populations
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel